中外医疗
中外醫療
중외의료
CHINA FOREIGN MEDICAL TREATMENT
2015年
23期
30-31
,共2页
ⅢB期结肠癌组织%高迁移率族蛋白1%表达%临床意义
ⅢB期結腸癌組織%高遷移率族蛋白1%錶達%臨床意義
ⅢB기결장암조직%고천이솔족단백1%표체%림상의의
StageⅢB colon cancer tissue%High mobility group box-1 protein%Expression%Clinical significance
目的：探讨ⅢB期结肠癌组织中高迁移率族蛋白1的表达及其临床意义。方法整群选取该院收治的72例ⅢB期结肠癌患者资料进行分析，采用免疫组织化学染色及免疫双染色技术对高迁移率族蛋白1表达及淋巴细胞浸润情况进行分析，研究高迁移率族蛋白1在ⅢB期结肠癌患者中的表达及临床意义。结果在结肠癌组织HMGB1弱表达标本(-、+)中CD3+、CD45RO+淋巴细胞的浸润密度明显低于HMGB1强表达标本((++，+++)(P<0.05)；HMGB1和性别、年龄、原发肿瘤、病理分级等差异不显著(P>0.05)。结论高迁移率族蛋白1核质共表达时淋巴细胞清润较少，且患者生存率降低，能够反应ⅢB期结肠癌患者预后，值得推广使用。
目的：探討ⅢB期結腸癌組織中高遷移率族蛋白1的錶達及其臨床意義。方法整群選取該院收治的72例ⅢB期結腸癌患者資料進行分析，採用免疫組織化學染色及免疫雙染色技術對高遷移率族蛋白1錶達及淋巴細胞浸潤情況進行分析，研究高遷移率族蛋白1在ⅢB期結腸癌患者中的錶達及臨床意義。結果在結腸癌組織HMGB1弱錶達標本(-、+)中CD3+、CD45RO+淋巴細胞的浸潤密度明顯低于HMGB1彊錶達標本((++，+++)(P<0.05)；HMGB1和性彆、年齡、原髮腫瘤、病理分級等差異不顯著(P>0.05)。結論高遷移率族蛋白1覈質共錶達時淋巴細胞清潤較少，且患者生存率降低，能夠反應ⅢB期結腸癌患者預後，值得推廣使用。
목적：탐토ⅢB기결장암조직중고천이솔족단백1적표체급기림상의의。방법정군선취해원수치적72례ⅢB기결장암환자자료진행분석，채용면역조직화학염색급면역쌍염색기술대고천이솔족단백1표체급림파세포침윤정황진행분석，연구고천이솔족단백1재ⅢB기결장암환자중적표체급림상의의。결과재결장암조직HMGB1약표체표본(-、+)중CD3+、CD45RO+림파세포적침윤밀도명현저우HMGB1강표체표본((++，+++)(P<0.05)；HMGB1화성별、년령、원발종류、병리분급등차이불현저(P>0.05)。결론고천이솔족단백1핵질공표체시림파세포청윤교소，차환자생존솔강저，능구반응ⅢB기결장암환자예후，치득추엄사용。
Objective To discuss the expression of high mobility group box-1 protein (HMGB1) in stageⅢB colon cancer tissue and its clinical significance. Methods The clinical data of 72 patients with stage ⅢB colon cancer was selected as the research object. The expression of HMGB1 in their colon cancer tissue and their lymphocytic infiltrates were analyzed by immunohistochemical staining method and double immunostaining technique to study its clinical significance. Results Infiltrated density of CD3+, CD45RO+ lymphocytes was obviously lower in the colon cancer tissues in which HMGB1 was weekly expressed (-, +) than those in which HMGB1 was strongly expressed (++, +++) (P<0.05); but there were no statistically significant correlations between the expression of HMGB1 and age, gender, primary tumor, pathological grade(P>0.05). Conclusion The week expression of HMGB1 was is always accompanied by fewer lymphocytic infiltration and lower survival rate, which can be applied in indicating the prognosis of patients with stageⅢB colon cancer.
